先声药业

Simcere will fund this research to discover first-in-class disease-modifying molecules to treat Parkinson’s disease, and license-in with 100% global interest in the FIC product if successful.

先声药业获大中华地区开发、生产和商业化该产品所有适应症的独家权利。康乃德生物医药将保留该产品在协议地区以外的权利，并将继续负责并完成正在进行的临床试验。